Review of decisions

Debbie Adams

GAVI Alliance Board Meeting
Geneva, Switzerland, 11-12 June 2013
Decision 1: Board/Committee member appointments (1/3)

- The GAVI Alliance Board:

  (a) **Appointed** the following Board members:

  - **Joan Awunyo-Akaba** as Board Member representing civil society organisations in the seat currently held by Alan Hinman effective 1 July 2013 until 30 June 2015.

  - **Jenny Da Rin** as Board Member representing the Australia, Japan, Korea and the United States of America donor constituency in the seat currently held by Robert Clay effective 1 July 2013 until 30 June 2015.

  - **Donal Brown** as Board Member representing the United Kingdom, Canada and Ireland donor constituency in the seat currently held by Simon Bland effective 1 July 2013 until 1 July 2016.
Decision 1: Board/Committee member appointments (2/3)

(b) **Appointed** the following Alternate Board members:

- **Naveen Thacker** as Alternate Board Member to Joan Awunyo-Akaba representing civil society organisations in the seat currently held by Joan Awunyo-Akaba effective 1 July 2013 until 30 June 2015.

- **Robert Clay** as Alternate Board Member to Jenny Da Rin representing the Australia, Japan, Korea and the United States of America donor constituency in the seat currently held by Jenny Da Rin effective 1 July 2013 until 30 June 2015.

- **María del Socorro Interiano Portillo** of Honduras as Alternate Board Member to Andrei Usatii of Moldova representing the developing country constituency in the seat currently held by Nila Heredia effective 1 July 2013 until 31 December 2015.

- **Fuad Juliman** as Alternate Board Member to Mahima Datla representing the developing country vaccine industry in the seat currently held by Suresh Jadhav effective 1 July 2013 until 31 July 2014.
Decision 1: Board/Committee member appointments (3/3)

(c) **Reappointed** the following person as an Independent expert to the Evaluation Advisory Committee:

- Gonzalo Hernandez effective immediately until 31 December 2015.

(d) **Appointed** the following person as a Committee delegate of the Programme and Policy Committee until the Committee is refreshed:

- Raj Baisya effective immediately in the seat currently held by Abigail Robinson (UK).

(e) **Appointed** the following person as member of the Governance Committee:

- Donal Brown in the seat currently held by Simon Bland effective 1 July 2013 until the Committee is refreshed.

(f) **Appointed** the following person as Chair of the Programme and Policy Committee:

- Richard Sezibera in the seat currently held by Gustavo Gonzalez-Canali effective 1 July 2013 until the Committee is refreshed.
Decision 2: Committee chairs and members terms: Changes to By-Laws and Committee Charters (1/5)

- The GAVI Alliance Board:
  
  (a) **Amended** the second sentence of Article 4.2 of the By-Laws as follows:

  - Each of the Board Committees shall have a presiding chair who shall be one of the Board Members and shall be appointed annually once every two years by the Board unless otherwise provided in the Statutes, By-Laws or Charter of the relevant Committee.
Decision 2: Committee chairs and members terms: Changes to By-Laws and Committee Charters (2/5)

(b) **Amended** the first sentence of Section 2 of the Charter of Executive Committee as follows:

- **Executive Committee members shall normally sit on the Executive Committee for three two years and may be reappointed for a single term, provided that an Eligible Organisation (or group of Eligible Organisations) or Eligible Constituency shall be entitled, in accordance with Article 10 of the Statutes, to have the same person(s) serve as its Executive Member(s) for such additional time as it shall desire and shall be entitled to replace its member(s) as it shall desire.**
Decision 2: Committee chairs and members terms: Changes to By-Laws and Committee Charters (3/5)

(c) **Amended** the first paragraph of Section 2 of the Charters of the Audit and Finance Committee, Investment Committee, and Programme and Policy Committee as follows:

- *The Committee shall be a Standing Committee of the Board and Article 4 of the By-Laws shall govern Committee member appointment, removal and resignation; all members shall be appointed on an annual basis once every two years, with renewable terms. Further the Committee shall consist of at least three Board Members/Alternates.*
Decision 2: Committee chairs and members terms: Changes to By-Laws and Committee Charters (4/5)

(d) **Amended** the first paragraph of Section 2 of the Charter of the Governance Committee as follows:

- **The Committee shall be a Standing Committee of the Board and Article 4 of the By-Laws shall govern Committee member appointment, removal and resignation; all members shall be appointed on an annual basis once every two years, with renewable terms. The Committee shall consist of at least three members. The Board Vice Chair shall also serve as Governance Committee Chair and a voting member of the Governance Committee (subject to the restrictions imposed by Article 4.2 of the By-Laws).**
Decision 2: Committee chairs and members terms: Changes to By-Laws and Committee Charters (5/5)

(e) **Amended** the second sentence of Section 2 of the Charter of the Evaluation Advisory Committee as follows:

- *The Board shall select the Committee Chair ("Chair") and members who shall serve at the pleasure of the Board appoint all members once every two years, both with renewable terms.*
Decision 3: Revision to the Investment Committee Charter

The GAVI Alliance Board:

Amended the Investment Committee Charter as follows:

- Bullet 1 of Section 4 is deleted in its entirety and replaced with:

  Review and set GAVI’s Investment Policy, asset allocation, investment goals and objectives from time to time.

- The following bullet is added to Section 4:

  Report regularly to the Board on any changes in the Investment Policy prior to implementation of the Policy, and on the Committee’s activities and actions, as appropriate.

- Bullet 3 of Section 4 is deleted in its entirety.
Decision 4: Amendment to the Programme Funding Policy

- The GAVI Alliance Board:
  - **Approved** the amended GAVI Programme Funding Policy attached as Annex 1 to Doc 02e.
Decision 5: Internal Audit reporting lines and terms of reference

- The GAVI Alliance Board:
  - Approved the reporting lines of the Internal Auditor, attached as Annex 1 to Doc 02f, and the revised Internal Audit Terms of Reference, attached as Annex 2 to Doc 02f.
Decision 6: Review of GAVI’s pilot prioritisation mechanism

- The GAVI Alliance Board:
  - Approved the revised prioritisation mechanism as attached to Doc 02g.
Decision 7: Vaccine investment strategy

- The GAVI Alliance Board:
  
  (a) **Endorsed** the evaluation criteria set out in Table 1 in Doc 07 for consideration in the Vaccine Investment Strategy (VIS) process.

  (b) **Decided** to narrow the choice of possible vaccine investment options (in addition to GAVI’s current portfolio) for further analysis in Phase II by prioritising vaccines based on health impact (mortality and morbidity), epidemic potential, and value for money (procurement cost per death averted). The Phase II analysis outcomes shall be benchmarked against the vaccines in GAVI’s current portfolio. As modelled in Phase I of the VIS and subject to further analysis in Phase II, influenza (for maternal immunisation), malaria and rabies vaccines are in the top tier of health impact outcomes; cholera and yellow fever vaccines are included on the basis of epidemic potential and value for money outcomes. Dengue, meningitis (serogroups CYW135) and measles (expanded investment), while diseases with epidemic potential, are excluded from further analysis because of a relatively high cost per death averted of the modelled strategy.
The GAVI Alliance Board:

(a) **Recognises** the importance of a strong partnership and complementarity between the GAVI Alliance and the Global Polio Eradication Initiative (GPEI) in eradicating polio based on a mutually agreed understanding of roles, responsibilities and results in countries;

(b) **Notes** the comparative advantage of the GAVI Alliance in new vaccine introductions, the importance of routine immunisation programmes and the integration of IPV into those programmes;

(c) **Recognises** the urgency of defining GAVI’s role in the Polio Eradication Endgame Strategy and Plan.
Decision 8: Polio and routine immunisation (2/8)

(d) **Supports** the GAVI Alliance playing a lead role in the introduction of IPV into routine immunisation services in 73 GAVI countries (See Annex 1) as part of the Polio Eradication Endgame Strategy and Plan in collaboration with GPEI. Consistent with previous Board decisions, the GAVI Alliance should work with countries using GAVI’s structures, policies and processes where possible;

(e) **Emphasises** that the financial and human resource implications of GAVI’s role in the introduction of IPV must be clearly identified. Funding for IPV introduction should not be taken from GAVI’s current resources.
Decision 8: Polio and routine immunisation (3/8)

(f) **Requests** the Secretariat, as a matter of urgency, in collaboration with GPEI to:

i. Initiate country dialogue on the introduction of IPV through national routine immunisation in accordance with recommendations by WHO and SAGE, prioritising countries most at risk for polio outbreaks; and

ii. Initiate preparations with relevant partners, including countries, for IPV procurement and implementation support.
Decision 8: Polio and routine immunisation (4/8)

(g) **Requests** the Secretariat to report to the Board and appropriate committees on the Alliance’s specific role and activities in the introduction of IPV in line with the Polio Eradication Endgame Strategy. This should consider the long-term implications to GAVI in terms of human/financial resources as well as potential risks to the implementation of existing programmes. The report should also include consideration of what role the GAVI Alliance could play in the longer-term in the following areas:

i. demand and supply forecasting;
ii. procurement;
iii. market shaping;
iv. risk implications and mitigation strategy;
v. routine immunisation system strengthening, health systems strengthening and vaccine introduction support;
vi. country introduction of IPV via routine immunisation.

(h) Based on the above, requests the Secretariat to present a longer term strategy on introduction of IPV to the Board as soon as possible, but no later than November 2013.
Decision 8: Polio and routine immunisation (5/8)

(i) **Delegates** to the Executive Committee the responsibility to take time sensitive decisions, in the short-term if necessary.

(j) **Calls upon donors to:**

- urgently clarify the use of the Polio Eradication Endgame funds to ensure that the costs to GAVI of implementing IPV in GAVI eligible and graduating countries (73) is fully funded without negatively impacting GAVI’s current strategic objectives.
Decision 8: Polio and routine immunisation (6/8) – Annex 1 (GAVI eligible countries)

- Afghanistan
- Bangladesh
- Benin
- Burkina Faso
- Burundi
- Cambodia
- Cameroon
- Central African Republic
- Chad
- Comoros
- Congo, Dem Republic of
- Côte d'Ivoire
- Djibouti
- Eritrea
- Ethiopia
- Gambia
- Ghana
- Guinea
- Guinea Bissau
- Haiti
- India
- Kenya
- Korea, DPR
- Kyrgyz Republic
- Lao PDR
- Lesotho
- Liberia
- Madagascar
- Malawi
- Mali
- Mauritania
- Mozambique
- Myanmar
- Nepal
- Nicaragua
- Niger
- Nigeria
- Pakistan
- Papua New Guinea
- Rwanda
Decision 8: Polio and routine immunisation (7/8) – Annex 1 (GAVI eligible countries)

- São Tomé e Príncipe
- Senegal
- Sierra Leone
- Solomon Islands
- Somalia
- Republic of Sudan
- South Sudan
- Tajikistan
- Tanzania
- Togo
- Uganda
- Uzbekistan
- Viet Nam
- Yemen
- Zambia
- Zimbabwe
Decision 8: Polio and routine immunisation (8/8) – Annex 1 (GAVI graduating countries)

- Angola
- Armenia
- Azerbaijan
- Bhutan
- Bolivia
- Congo Rep.
- Cuba
- Georgia
- Guyana
- Honduras
- Indonesia
- Kiribati
- Moldova
- Mongolia
- Sri Lanka
- Timor Leste
- Ukraine
Decision 9: Grant application, monitoring and review

- The GAVI Alliance Board:
  
  (a) **Approved** the principles and key elements of the proposed redesign of GAVI’s grant application, monitoring and review systems, as described in section B.3 of Doc 06 to the PPC as attached to Doc 12, with the first evaluation of the system taking place after one year of implementation.

  (b) **Approved** a High Level Review Panel consisting of senior level staff of the Secretariat, WHO and UNICEF, the IRC Chair and two other IRC members. Senior staff of other Alliance partners may be invited to the Review Panel, as participants or observers, as appropriate.

  (c) **Requested** the Secretariat to work with affiliated entities and partners to ensure launch of the new systems starting 1 January 2014, with all existing and new grants shifting to the new system following this date.
www.gavialliance.org